986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)

A.R.R He,J Lee,S.P Hack,M Morimoto,W Verret,C-H Hsu,K Numata,B-Y Ryoo,B Liu,K-H Lee,J Spahn

doi:10.1016/j.annonc.2020.08.1102

986P Efficacy of atezolizumab (atezo) + bevacizumab (bev) after disease progression with atezo monotherapy in patients with previously untreated, unresectable hepatocellular carcinoma (HCC)

A.R.R He, J Lee + Show 9 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.1102

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
Citations: 3	License type: publisher-specific-oa

Affiliation: Samsung Medical Center, Sungkyunkwan University, Kanagawa Prefectural Hospital Organization, National Taiwan University, Yokohama City University, Yokohama City University Medical Center, Asan Medical Center, Seoul National University Hospital

#Atezo Monotherapy #Unresectable Hepatocellular Carcinoma + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Atezo (anti-PD-L1) + bev (anti–VEGF) statistically significantly prolonged overall survival (OS) and progression-free survival (PFS) vs sorafenib in the phase III IMbrave150 study in patients with unresectable HCC. In the phase Ib study GO30140, atezo + bev statistically significantly increased PFS vs atezo. We present efficacy data from GO30140 patients who crossed over to atezo + bev following progression on atezo.

Full Text